Literature DB >> 19116099

Needlescopic ablation of small adrenal masses.

Eric Lauer1, Joseph J Del Pizzo, Jay D Raman.   

Abstract

Needlescopic adrenal ablative therapy is an attractive therapeutic option for the management of small adrenal masses. The spectrum of neoplasms that can be ablated includes isolated solid organ metastases (lung, kidney, liver), nonisolated but symptomatic (painful) adrenal metastasis, and small, nonmetastatic, hormonally active adrenal tumors. Moreover, needlescopic ablation offers an effective minimally morbid intervention for patients who are poor surgical candidates either due to advanced age and/or significant comorbid conditions. Ablative techniques described to date include radiofrequency ablation (RFA), cryoablation, and chemical ablation. Most procedures can be performed under percutaneous radiographic guidance on an outpatient basis. By and large, the bulk of clinical experience with adrenal ablation pertains to RFA. Successful ablation is usually dependent upon lesion size, with tumors 5 cm or smaller demonstrating the highest successful ablation rates. The most frequently described adverse sequelae of adrenal ablation are local tumor recurrences. However, many of these local recurrences can be managed by repeat ablation, with patients demonstrating durable oncologic outcomes.

Entities:  

Mesh:

Year:  2009        PMID: 19116099     DOI: 10.1007/s11934-009-0013-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  26 in total

1.  Percutaneous ethanol ablation of an adrenal tumor.

Authors:  D D Maki; Z J Haskal; A Matthies; J Langer; H L Nisenbaum; D Vaughn; A Alavi
Journal:  AJR Am J Roentgenol       Date:  2000-04       Impact factor: 3.959

2.  Radiofrequency ablation of metastatic lesions in adrenocortical cancer.

Authors:  J Abraham; T Fojo; B J Wood
Journal:  Ann Intern Med       Date:  2000-08-15       Impact factor: 25.391

Review 3.  Radiofrequency ablation beyond the liver.

Authors:  Ziv Neeman; Bradford J Wood
Journal:  Tech Vasc Interv Radiol       Date:  2002-09

4.  Successful percutaneous radiofrequency ablation of adrenal metastasis from hepatocellular carcinoma.

Authors:  Hiroaki Haga; Takafumi Saito; Kazuo Okumoto; Kazuhiko Sugahara; Tadashi Takeda; Koji Saito; Hitoshi Togashi; Sumio Kawata
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

5.  Appropriate premedication risk reduction during adrenal ablation.

Authors:  Deepak Sudheendra; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2006-08       Impact factor: 3.464

6.  The role of surgery in the treatment of clinically isolated adrenal metastasis.

Authors:  S H Kim; M F Brennan; P Russo; M E Burt; D G Coit
Journal:  Cancer       Date:  1998-01-15       Impact factor: 6.860

7.  Hypertensive crisis in a patient undergoing percutaneous radiofrequency ablation of an adrenal mass under general anesthesia.

Authors:  Eduardo N Chini; Michael J Brown; Michael A Farrell; J William Charboneau
Journal:  Anesth Analg       Date:  2004-12       Impact factor: 5.108

8.  CT-guided percutaneous chemical ablation of adrenal neoplasms.

Authors:  Yue-Yong Xiao; Jin-Lin Tian; Jia-Kai Li; Li Yang; Jin-Shan Zhang
Journal:  AJR Am J Roentgenol       Date:  2008-01       Impact factor: 3.959

9.  EUS-guided alcohol ablation of left adrenal metastasis from non-small-cell lung carcinoma.

Authors:  Everson L A Artifon; Antonio M Lucon; Paulo Sakai; Rene Gerhardt; Miguel Srougi; Teresa Takagaki; Shinichi Ishioka; Manoop S Bhutani
Journal:  Gastrointest Endosc       Date:  2007-12       Impact factor: 9.427

10.  Adrenal neoplasms: CT-guided radiofrequency ablation--preliminary results.

Authors:  William W Mayo-Smith; Damian E Dupuy
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

View more
  1 in total

1.  Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.

Authors:  Daisuke Iitaka; Atsushi Shiozaki; Hitoshi Fujiwara; Daisuke Ichikawa; Kazuma Okamoto; Shuhei Komatsu; Yasutoshi Murayama; Hisashi Ikoma; Yoshiaki Kuriu; Masayoshi Nakanishi; Toshiya Ochiai; Yukihito Kokuba; Teruhisa Sonoyama; Eigo Otsuji
Journal:  Surg Today       Date:  2012-07-01       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.